Cardiovascular Effects of Parathyroid Hormone Analogues in Chronic Hypoparathyroidism
Key facts
- Who runs it
- National and Kapodistrian University of Athens
- Where
- Greece2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 210 people, planned
- Started
- 1 Apr 2026
- Expected to end
- 31 Dec 2028
- Type of study
- Observational, 4 groups
- Treatments tested
- Arterial stiffness in the aorta by measurement of pulse wave velocity
- Central blood pressures and reflected waves in the aorta
- Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques
- Imaging of the sublingual microcirculation (GlycoCheck system)
- Ankle-brachial index (ABI)
- Fundoscopy
- Cardiac Ultrasonography Study
- Local shear stress in brachial and carotid artery
- Peripheral and aortic office and ambulatory blood pressure
- Circulating levels of myocardial biomarkers
- Evaluation of Calcium metabolism
- Record updated
- 16 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Cross sectional arm: Baseline State: Adults (≥18y) with chronic HypoPT (≥12 months) currently treated with conventional therapy or palopegteriparatide for more than one year; -Prospective Follow-up: Adults (≥18y) with chronic HypoPT (≥12 months) currently treated with conventional therapy and about to start treatment with palopegteriparatide willing to undergo baseline measurements (prior to the first dose) and repeat measurements at 3 and 12 months
Who cannot take part
- Bone Health: Any metabolic bone disease other than hypoparathyroidism (excluding osteoporosis)
- Renal Function: CKD Stage 3 or higher (eGFR < 60 mL/min/1.73 m²)
- Uncontrolled Risk Factors:; SBP > 180/100 mmHg; Uncontrolled endocrine diseases (e.g., hyper- or hypothyroidism, diabetes mellitus type 2 with HbA1c>7.5%)
- Documented Atrial Fibrillation (ECG)
- Contraindication to long acting PTH analogue as per product labeling
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this study is to evaluate cardiovascular effects of long-acting parathyroid hormone (PTH) analogues in adults with chronic hypoparathyroidism. The main questions it aims to answer are:
Read full original descriptionShow less
* Do patients with hypoparathyroidism have increased arterial stiffness and markers of subclinical cardiovascular injury compared to healthy individuals? * Does treatment with a long-acting PTH analogue improve vascular and cardiac function over time compared to conventional therapy? This is a multi-center study with two parts: a cross-sectional comparison and a 12-month prospective follow-up. Adults with chronic hypoparathyroidism and matched healthy controls will undergo clinical evaluation, vascular measurements, cardiac imaging, and blood tests.
In the prospective part, patients that just started long-acting PTH analogue therapy based on their treating physicians choice will be followed for 12 months, with repeat assessments at baseline, 3 months, and 12 months to evaluate changes in cardiovascular markers.
The 4 groups in the trial
- Patients with chronic hypoparathyroidism under conventional treatment (disease control)
20-30 Hypo-PT patients aged ≥18 on conventional HypoPT therapy with any dose of activated vitamin D and calcium and native vitamin D supplements for at least 12 months
Treatment: Arterial stiffness in the aorta by measurement of pulse wave velocity, Central blood pressures and reflected waves in the aorta, Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques, Imaging of the sublingual microcirculation (GlycoCheck system), Ankle-brachial index (ABI), Fundoscopy, Cardiac Ultrasonography Study, Local shear stress in brachial and carotid artery, Peripheral and aortic office and ambulatory blood pressure, Circulating levels of myocardial biomarkers, and Evaluation of Calcium metabolism
- Patients with chronic hypoparathyroidism under treatment with palopegteriparatide
40-50 Hypo-PT patients aged ≥18 treated with Palopegteriparatide (TransCon PTH) for at least 12 months
Treatment: Arterial stiffness in the aorta by measurement of pulse wave velocity, Central blood pressures and reflected waves in the aorta, Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques, Imaging of the sublingual microcirculation (GlycoCheck system), Ankle-brachial index (ABI), Fundoscopy, Cardiac Ultrasonography Study, Local shear stress in brachial and carotid artery, Peripheral and aortic office and ambulatory blood pressure, Circulating levels of myocardial biomarkers, and Evaluation of Calcium metabolism
- Healthy controls
Healthy controls: 170 Healthy controls matched with group 1 and group 2 for age, sex, CVD presence, propensity score, DM2, renal function, BMI and SBP, retrospectively recruited from the Athens Angiometabolic Cohort
Treatment: Arterial stiffness in the aorta by measurement of pulse wave velocity, Central blood pressures and reflected waves in the aorta, Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques, Imaging of the sublingual microcirculation (GlycoCheck system), Ankle-brachial index (ABI), Fundoscopy, Cardiac Ultrasonography Study, Local shear stress in brachial and carotid artery, Peripheral and aortic office and ambulatory blood pressure, Circulating levels of myocardial biomarkers, and Evaluation of Calcium metabolism
- Patients with chronic hypoparathyroidism switching from conventional therapy to palopegteriparatide
20 patients starting treatment with palopegteriparatide, previously on conventional treatment
Treatment: Arterial stiffness in the aorta by measurement of pulse wave velocity, Central blood pressures and reflected waves in the aorta, Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques, Imaging of the sublingual microcirculation (GlycoCheck system), Ankle-brachial index (ABI), Fundoscopy, Cardiac Ultrasonography Study, Local shear stress in brachial and carotid artery, Peripheral and aortic office and ambulatory blood pressure, Circulating levels of myocardial biomarkers, and Evaluation of Calcium metabolism
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Long-acting PTH Analogues on Markers of Subclinical Arterial and Myocardial Injury in Chronic Hypoparathyroidism..
- Record updated
- 16 July 2026